Following the investigation of the effects of both CB2 agonist AM1241 and CB2 antagonist AM630 on the inflammation and the metabolic adaptations in obesity, it is concluded that both treatments reduce circulating leptin in the absence of weight loss and alter the expression of genes that mediate the thermogenic response. The gene discussed is LEP; the disease is Obesity.